Annovis Bio Inc. (NYSE: ANVS) will deliver three presentations at the 19th Clinical Trials on Alzheimer’s Disease (CTAD) conference, scheduled for Nov. 16-19, 2026, in Boston. The company announced the presentations will focus on its investigational oral therapy buntanetap, covering its mechanism of action, the design and baseline characteristics of its pivotal Phase 3 study in early Alzheimer’s disease, and the use of artificial intelligence to predict blood-brain barrier permeability of late-stage Alzheimer’s drug candidates.
The lineup includes an oral presentation on Nov. 19 by Alexander Morin, director of strategic communications, and two poster presentations on Nov. 16-17, one of which will be delivered by Chief Scientific Officer Cheng Fang. According to Annovis, these presentations reflect ongoing progress in the buntanetap development program as the company approaches a pivotal clinical data readout in early 2027 and prepares for a New Drug Application.
The timing of the CTAD presentations is significant because it places Annovis’s clinical strategy before an audience of Alzheimer’s researchers, clinicians, and industry stakeholders at a critical juncture. With a pivotal readout expected in early 2027, the conference offers a venue to detail the scientific rationale and trial design that will underpin the company’s regulatory submission. The inclusion of an AI-driven approach to predicting blood-brain barrier permeability also signals Annovis’s interest in leveraging advanced analytics to optimize late-stage drug candidate selection, a factor that could influence future development decisions.
Buntanetap is an investigational once-daily oral therapy designed to inhibit the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism. By addressing underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. The company is headquartered in Malvern, Pennsylvania, and is a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease. For more information, visit www.annovisbio.com and follow the company on LinkedIn, YouTube, and X.
For investors, the CTAD presentations may provide deeper visibility into the Phase 3 trial’s baseline characteristics and the scientific foundation of buntanetap, potentially affecting perceptions of risk and timeline. The latest news and updates relating to ANVS are available in the company’s newsroom at https://nnw.fm/ANVS. The full press release can be viewed at https://nnw.fm/2k4SQ.
The announcement was distributed via NetworkNewsWire, a communications platform focused on financial news and content distribution. NetworkNewsWire is part of the Dynamic Brand Portfolio at IBN, which provides wire solutions through InvestorWire and other services. Full terms of use and disclaimers are available at https://www.NetworkNewsWire.com/Disclaimer.
